Fluorodeoxyglucose

Phase 3Radiopharmaceutical

SStanford University

Fluorodeoxyglucose is one of 77 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Esophageal CancerPhase 1

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Fluorodeoxyglucose

SStanford University

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Norvir

AbbVie

Preclinical

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Efficacy and Safety

NCT04943211

Clinical

Trials by Indication[1]

Esophageal Cancer1 trial

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

Terminated·SStanford University·Phase 1·NCT00368329·4 enrolled

Efficacy and Safety1 trial

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

Recruiting·AAnna Raciborska·Phase 3·NCT04943211·150 enrolled

Lymphoma1 trial

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Terminated·PPentixapharm AG·Phase 3·NCT06125028·13 enrolled

Alzheimer's Disease1 trial

Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting·IIndiana University··NCT03507257·850 enrolled

PET/CT1 trial

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

Completed·YYale University·Phase 1·NCT03048097·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Fluorodeoxyglucose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorodeoxyglucose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorodeoxyglucose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 3[1]
Company: SStanford University

Fluorodeoxyglucose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Esophageal Cancer1 trial

Efficacy and Safety1 trial

Lymphoma1 trial

Alzheimer's Disease1 trial

PET/CT1 trial

References

Drug Info

Quick Facts

Related News